NCT06924606

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) in Combination With or Without JS004 or Docetaxel in Advanced Non-small Cell Lung Cancer With Disease Progression During or After the Treatment of Platinum-based Chemotherapy and Immunotherapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.

Conditions

• Advanced NSCLC

Interventions

Type	Name	Description
DRUG	JS207 injection +docetaxel	Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
DRUG	JS207 injection +JS004 injection	Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
DRUG	JS207 injection	Patients receive JS207 10mg/kg or other dosage.

Timeline

• Start date: 2025-07-15
• Primary completion: 2026-06-26
• Completion: 2026-06-26
• First posted: 2025-04-11
• Last updated: 2026-02-06

Locations

18 sites across 1 country: China